FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007039430> ?p ?o ?g. }

• W2007039430 endingPage "34828" @default.
• W2007039430 startingPage "34819" @default.
• W2007039430 abstract "Opioids display ligand-specific differences in the time course of ERK1/2 signaling. Whereas full agonists, like etorphine, induce only transient activation of ERK1/2, the partial agonist morphine mediates persistent stimulation of mitogenic signaling. Here we report that in stably δ-opioid receptor (DOR)-expressing HEK293 (HEK/DOR) cells, the transient nature of etorphine-induced ERK1/2 signaling is due to desensitization of epidermal growth factor (EGF) receptor-mediated activation of the Ras/Raf-1/ERK1/2 cascade. Desensitization of ERK1/2 activity by etorphine is associated with down-regulation of EGF receptors, an effect mediated by the ubiquitin ligase c-Cbl. In contrast, chronic morphine treatment failed to desensitize EGF receptors, resulting in unimpeded ERK1/2 signaling. The failure of morphine to desensitize ERK1/2 signaling is mediated by persistent activation of c-Src, which induces degradation of c-Cbl. The role of c-Src in opioid-specific ERK1/2 signaling is further demonstrated by pretreatment of the cells with PP2 and SKI-I as well as overexpression of a dominant negative c-Src mutant (c-Src(dn)) or a c-Src-resistant c-Cbl mutant (CblY3F), both of which facilitate desensitization of ERK1/2 signaling by morphine. Conversely, overexpression of c-Src as well as down-regulation of c-Cbl by small interfering RNA results in persistent etorphine-induced stimulation of ERK1/2 activity. Subcellular fractionation experiments finally attributed the ability of morphine to persistently activate c-Src to its redistribution from Triton X-100-insensitive membrane rafts to DOR and EGF receptor containing high density membrane compartments implicated in ERK1/2 signaling. These results demonstrate that agonist-specific differences in the temporal and spatial pattern of c-Src activation determine the kinetics of DOR-mediated regulation of ERK1/2 signaling. Opioids display ligand-specific differences in the time course of ERK1/2 signaling. Whereas full agonists, like etorphine, induce only transient activation of ERK1/2, the partial agonist morphine mediates persistent stimulation of mitogenic signaling. Here we report that in stably δ-opioid receptor (DOR)-expressing HEK293 (HEK/DOR) cells, the transient nature of etorphine-induced ERK1/2 signaling is due to desensitization of epidermal growth factor (EGF) receptor-mediated activation of the Ras/Raf-1/ERK1/2 cascade. Desensitization of ERK1/2 activity by etorphine is associated with down-regulation of EGF receptors, an effect mediated by the ubiquitin ligase c-Cbl. In contrast, chronic morphine treatment failed to desensitize EGF receptors, resulting in unimpeded ERK1/2 signaling. The failure of morphine to desensitize ERK1/2 signaling is mediated by persistent activation of c-Src, which induces degradation of c-Cbl. The role of c-Src in opioid-specific ERK1/2 signaling is further demonstrated by pretreatment of the cells with PP2 and SKI-I as well as overexpression of a dominant negative c-Src mutant (c-Src(dn)) or a c-Src-resistant c-Cbl mutant (CblY3F), both of which facilitate desensitization of ERK1/2 signaling by morphine. Conversely, overexpression of c-Src as well as down-regulation of c-Cbl by small interfering RNA results in persistent etorphine-induced stimulation of ERK1/2 activity. Subcellular fractionation experiments finally attributed the ability of morphine to persistently activate c-Src to its redistribution from Triton X-100-insensitive membrane rafts to DOR and EGF receptor containing high density membrane compartments implicated in ERK1/2 signaling. These results demonstrate that agonist-specific differences in the temporal and spatial pattern of c-Src activation determine the kinetics of DOR-mediated regulation of ERK1/2 signaling." @default.
• W2007039430 created "2016-06-24" @default.
• W2007039430 creator A5024637715 @default.
• W2007039430 creator A5054506022 @default.
• W2007039430 date "2009-12-01" @default.
• W2007039430 modified "2023-10-16" @default.
• W2007039430 title "Down-regulation of c-Cbl by Morphine Accounts for Persistent ERK1/2 Signaling in δ-Opioid Receptor-expressing HEK293 Cells" @default.
• W2007039430 cites W1535722786 @default.
• W2007039430 cites W1733018497 @default.
• W2007039430 cites W1776637350 @default.
• W2007039430 cites W1909995282 @default.
• W2007039430 cites W1930762285 @default.
• W2007039430 cites W1964628210 @default.
• W2007039430 cites W1965939769 @default.
• W2007039430 cites W1967193735 @default.
• W2007039430 cites W1969785844 @default.
• W2007039430 cites W1971849987 @default.
• W2007039430 cites W1973006691 @default.
• W2007039430 cites W1989224940 @default.
• W2007039430 cites W1992251909 @default.
• W2007039430 cites W1995654020 @default.
• W2007039430 cites W1999306810 @default.
• W2007039430 cites W2001721435 @default.
• W2007039430 cites W2004759810 @default.
• W2007039430 cites W2004874751 @default.
• W2007039430 cites W2007277452 @default.
• W2007039430 cites W2008351137 @default.
• W2007039430 cites W2018896819 @default.
• W2007039430 cites W2025791161 @default.
• W2007039430 cites W2031835913 @default.
• W2007039430 cites W2033140304 @default.
• W2007039430 cites W2033945588 @default.
• W2007039430 cites W2048105534 @default.
• W2007039430 cites W2050141745 @default.
• W2007039430 cites W2050863125 @default.
• W2007039430 cites W2052009158 @default.
• W2007039430 cites W2056881172 @default.
• W2007039430 cites W2066162119 @default.
• W2007039430 cites W2073736976 @default.
• W2007039430 cites W2074877259 @default.
• W2007039430 cites W2075857898 @default.
• W2007039430 cites W2077218147 @default.
• W2007039430 cites W2082463787 @default.
• W2007039430 cites W2086434511 @default.
• W2007039430 cites W2087282284 @default.
• W2007039430 cites W2087311403 @default.
• W2007039430 cites W2088533559 @default.
• W2007039430 cites W2090895449 @default.
• W2007039430 cites W2092099338 @default.
• W2007039430 cites W2092556174 @default.
• W2007039430 cites W2095377029 @default.
• W2007039430 cites W2100233587 @default.
• W2007039430 cites W2101362932 @default.
• W2007039430 cites W2101413460 @default.
• W2007039430 cites W2102355451 @default.
• W2007039430 cites W2102361757 @default.
• W2007039430 cites W2102389784 @default.
• W2007039430 cites W2110807916 @default.
• W2007039430 cites W2120072474 @default.
• W2007039430 cites W2126718411 @default.
• W2007039430 cites W2127846911 @default.
• W2007039430 cites W2130135920 @default.
• W2007039430 cites W2140538678 @default.
• W2007039430 cites W2143891754 @default.
• W2007039430 cites W2144026823 @default.
• W2007039430 cites W2155021550 @default.
• W2007039430 cites W2163304919 @default.
• W2007039430 cites W2167365571 @default.
• W2007039430 cites W2169290377 @default.
• W2007039430 cites W2269570071 @default.
• W2007039430 cites W4300976536 @default.
• W2007039430 doi "https://doi.org/10.1074/jbc.m109.042937" @default.
• W2007039430 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2787344" @default.
• W2007039430 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19828455" @default.
• W2007039430 hasPublicationYear "2009" @default.
• W2007039430 type Work @default.
• W2007039430 sameAs 2007039430 @default.
• W2007039430 citedByCount "14" @default.
• W2007039430 countsByYear W20070394302013 @default.
• W2007039430 countsByYear W20070394302014 @default.
• W2007039430 countsByYear W20070394302015 @default.
• W2007039430 countsByYear W20070394302016 @default.
• W2007039430 countsByYear W20070394302017 @default.
• W2007039430 countsByYear W20070394302018 @default.
• W2007039430 countsByYear W20070394302019 @default.
• W2007039430 countsByYear W20070394302020 @default.
• W2007039430 countsByYear W20070394302023 @default.
• W2007039430 crossrefType "journal-article" @default.
• W2007039430 hasAuthorship W2007039430A5024637715 @default.
• W2007039430 hasAuthorship W2007039430A5054506022 @default.
• W2007039430 hasBestOaLocation W20070394301 @default.
• W2007039430 hasConcept C108636557 @default.
• W2007039430 hasConcept C134018914 @default.
• W2007039430 hasConcept C170493617 @default.
• W2007039430 hasConcept C174510640 @default.
• W2007039430 hasConcept C185592680 @default.
• W2007039430 hasConcept C24998067 @default.
• W2007039430 hasConcept C2778750930 @default.

• next